Cervical cancer (CC) as a single diagnostic entity exhibits differences in clinical behavior and poor outcomes in response to therapy in advanced tumors. Although infection of high-risk human papillomavirus is recognized as an important initiating event in cervical tumorigenesis, stratification of CC into subclasses for progression and response to treatment remains elusive. Existing knowledge of genetic, epigenetic and transcriptional alterations is inadequate in addressing the issues of diagnosis, progression and response to treatment. Recent technological advances in high-throughput genomics and the application of integrative approaches have greatly accelerated gene discovery, facilitating the identification of molecular targets. In this article, we discuss the results obtained by preliminary integrative analysis of DNA copy number increases and gene expression, utilizing the two most common copy number-gained regions of 5p and 20q in identifying gene targets in CC. These analyses provide insights into the roles of genes such as RNASEN, POLs and SKP2 on 5p, KIF3B, RALY and E2F1 at 20q11.2 and CSE1L, ZNF313 and B4GALT5 at 20q13.13. Future integrative applications using additional datasets, such as mutations, DNA methylation and clinical outcomes, will raise the promise of accomplishing the identification of biological pathways and molecular targets for therapies for patients with CC.
Table 1. Genomic copy number amplifications, gains and losses identified by comparative genomic hybridization and loss of heterozygosity approaches in cervical cancer.

| Alteration          | Invasive cancer                                                                 | Precancer | Potential genes (region: gene) | Ref.          |
|---------------------|----------------------------------------------------------------------------------|-----------|--------------------------------|---------------|
| **Amplifications†** |                                                                                  |           |                                |               |
| Recurrent           | 3q21, 3q26–q29, 5p, 7q22, 8q23–q24, 8q24.3, 9p22, 9p23–24, 10q21, 11q13, 11q21, 11q22–23, 12p13, 14q12, 17q12, 17q25, 19q13.1, 20q11.2, 20q13.1 | None      | 3q27–29: RFC4, MUC4, HRASLS    |               |
|                     |                                                                                  |           | 5p: ARS8, RPL37, SKP2, OSMR, TARS, RAD1, SUB1, RNASEN, POL5, SDHA, TRIO, NDUF56, TRIP13, PDCD6, RAI14, SLC2A7, DAP, MYO10, BASP1, NNT, TARS, PAIP1, CCT5, NDUF56, BRD9, FASTKD3, BXDC2 |               |
|                     |                                                                                  |           | 8q24: PTK2, RECQL4             |               |
|                     |                                                                                  |           | 11q22.2: MMP1, MMP13           |               |
|                     |                                                                                  |           | 17q12: EBB2                    |               |
|                     |                                                                                  |           | 20q13.1: ATP9A, DDX27, ADNP, B4GALT5, ZNF313, CSE1L, UBE2C |               |
|                     |                                                                                  |           | 20q11.1: C20orf20, GSS, POFUT1, AHCY, TPX2, ASXL1, E2F1, RALLY, KIF3B |               |
| Nonrecurrent        | 1q31, 2q32, 7p11, 10q24, 12q15, 16q23–q24, 17p11.2, 17q22, 18p11.2, 20p       | None      | 17q21–22: ABCCC3              |               |
| **Gains**           |                                                                                  |           |                                |               |
| Replicate studies   | 1q22–q23, 1q25.3–q32.1, 3q24–29, 5p12–p13, 6p, 7q11.22–q11.23, 7q31.1–q31.2, 8q24.13–q24.22, 9q33.2–q34.3, 17q25.1–q25.2, 17q21–q22, 19q13.3, 20q11.22–q11.21–q13.33, 20q11.21–q12, 20q13.12–q13.31, 20q12, Xp11.2–p11.3, Xq12, Xq22, Xq28 | 1, 3q24–29 | 19q13.3: LIG1                  |               |
|                     |                                                                                  |           |                                 |               |
| Nonreplicate studies| 1p33–35, 1p36, 1p31.3–p21.1, 1q12–31.1, 1q32.2–q44, 3q13–23, 3p26.3–p26.1, 3p14.3–p14.2, 3q21–22, 5q31–qter, 11q22, 12p13, 14q32, 15q, 16p, 16q22.1–q23.2, 19p13, 20p13–p11.21 | 1p36.11–p25.2, 1p31.3–p21.1, 1q25.3–q32.1, 1q32.2–q44, 3p26.3–p26.1, 3p14.3–p14.2, 3q11.2–q29, 7q31.1–q31.2, 20p13–p11.21 | 1p36: EPHB2 |               |
|                     |                                                                                  |           | 1q32.3–q32.1                   |               |
|                     |                                                                                  |           |                                 |               |
|                     |                                                                                  |           | 1p36: CDC5A                    | Supplementary  |
|                     |                                                                                  |           |                                 | online material‡ |
|                     |                                                                                  |           | 1p34: CDC5A                    |               |
|                     |                                                                                  |           |                                 |               |
|                     |                                                                                  |           | 1q22–23: AIM2                   |               |
|                     |                                                                                  |           |                                 |               |
|                     |                                                                                  |           | 5q31.3: CENTD3                  |               |
|                     |                                                                                  |           |                                 |               |
|                     |                                                                                  |           | 14q32.3: AKT1                   |               |
|                     |                                                                                  |           |                                 |               |
|                     |                                                                                  |           | 19p13.3: MARCA4                 |               |
|                     |                                                                                  |           |                                 |               |
|                     |                                                                                  |           | 3q21–23: DTX3L, PIK3R4, ATP2C1, SLC25A36 |               |
| **Losses**          |                                                                                  |           |                                |               |
| Replicate studies   | 2q23–q37, 3p12–23, 4p16.3–p16.1, 4, 4q, 4q28.3–q32.1, 4q13.3, 4q35.2, 4q28.2, 6q, 8p23.3, 8p12–21.3, 8q23.2–q33.2, 9p, 11p15.5, 11q13.3, 11q22.3–25, 13q12.11–13q14.3, 13q14.3–q21.33, 13q31.1–q31.3, 17p13.3, 18q11.2–18q23 | 2q35–qter, 3p12–21, 4, 4p16.3–p16.1, 4q31.21, 4q35.2 | 4q: PCDH110 |               |
| Nonreplicate studies| 1p32.3, 6p22–24, 10p, 10q11.23–q21.3, 16q24.2–q24.3, 17q25.3                  | 11q13.3, 11q23–qter, 16q24.2–q24.3, 17p13.3, 17q25.3, 19p13.11–q12 |               |               |

†Recurrent amplifications present in two or more tumors and nonrecurrent amplifications in only isolated cases.
‡See www.futuremedicine.com/doi/suppl/10.2217/FON.10.114.
The changes listed in Table 1 are of several classes of genomic alterations, resulting in copy number gains and losses. Amplification (≥5 copies) of specific regions of the genome is a common phenomenon in many human tumors targeting overexpression of dominantly acting genes [7]. To date, the extent of gene amplification, as well as the genes involved, are not completely realized in CC. However, upon review of the literature on amplifications, we identified a total of 20 recurrent and ten nonrecurrent amplifications (Table 1) [8,9]. A number of potential genes mapped to these amplicons have also been identified. However, so far, none of these were proven to be target genes, owing to insufficient biological evidence for contribution as cancer genes in CC.

A similar situation exists for copy number changes resulting in gains (>2.5 copies) or losses (<1.5 copies) of specific genomic regions (Table 1). For example, 2q33–q37: CFLAR, CASP10, PP1R7B; 3p13–p24: FHIT, CTNNB1, TJP2, RASSF1A, RARβ; 4p: SLIT2, 6p21–p23: CD83, TAP1, NOL7, HLA class I; 9q21: p16/INK4a; 10q23.3: PTEN, 11q13–q24: MEN1, INT2, TRIM29, POUF3; 13q14: RB, 17p13: TP53, 17q11: CCL2. A large body of data on genetic deletions has been derived either by loss of heterozygosity or comparative genomic hybridization/array-based studies. A large number of deleted regions meeting the criteria that we applied (>20% cases with deletion and/or confirmed by more than one study) have also been reported. These findings of complex patterns of genetic losses suggest loss of function of one or more proliferation-regulating genes in each of these regions and their involvement in malignant progression of cervical epithelium. Although the expression profiling allowed the identification of a subset of candidate genes, with loss accompanied by expression changes in invasive cancer, these genes have not been further refined by analysis in additional tumors. For example, 2q33–q37: CFLAR, CASP10, PP1R7B; 3p13–p24: FHIT, CTNNB1, TJP2, RASSF1A, RARβ: 4p: SLIT2, 6p21–p23: CD83, TAP1, NOL7, HLA class I; 9q21: p16/INK4a; 10q23.3: PTEN, 11q13–q24: MEN1, INT2, TRIM29, POUF3; 13q14: RB, 17p13: TP53, 17q11: CCL2.
by decreased expression, no known tumor-suppressor genes with evidence of mutations in the second allele have been implicated thus far in CC, with the exception of rare instances for mutations in TP53 at 17p13, CDKN2A at 9p21 and PTEN at 10q23.3 (Tables 1 & 2).

As stated previously, mutations in tumor-suppressor genes are infrequently reported in CC and, in most instances, the mutations have not been confirmed by independent studies (Table 2). In the absence of mutations, tumor-suppressor genes may be inactivated in the recurrently deleted chromosomal regions by alternative mechanisms such as epigenetic modifications. One of the most well-established epigenetic changes is the promoter DNA hypermethylation-mediated gene silencing. A large number of genes (e.g., CDHI, DAPK, HIC1 and PCDH10) exhibiting promoter hypermethylation and associated downregulated expression of the gene have been reported in CC by multiple studies (Table 2) [13–16]. In addition, several other genes also shown to be methylated by a single study, where a subset of these cannot be completely excluded as targets in the deleted regions (Tables 1 & 2).

Based on the aforementioned discussion, the shortness of causal genetic mutations in CC, although its genomes exhibit complex chromosomal alterations is due to insufficient evidence offered by these studies to identify a cancer gene. Several supportive studies are usually required to establish the role of a specific gene, including finer physical and transcriptional mapping of the altered regions, examination of epigenetic mechanisms, functional analysis of target genes, correlations with clinical outcome and efficacy of drugs targeted against specific genes. For most genetic alterations reported in CC, such studies are lacking and often not feasible for obtaining these data. Added to this complexity, molecular heterogeneity within CC and biologic effects of multiple genes in each of the affected genomic regions constitute major obstacles in understanding its pathogenesis.

A number of studies have attempted using single high-throughput approaches to unravel the genetic, epigenetic and transcriptional alterations in CC [17–22]. As noted previously, these studies have revealed specific genomic, expression and epigenetic alterations. However, the failure to identify target genes in CC is largely owing to a lack of understanding of the relationship between how copy number and epigenetic markers influence transcription. How each change influence the other (e.g., amplification or copy number increases on gene overexpression or methylation markers and deletions on downregulated gene expression) remains largely unknown in CC. Integrative genomic analyses involving simultaneous assessment of DNA copy numbers, gene expression, mutations and methylation markers, such as cytosine methylation and histone tail modifications, have been demonstrated as potential approaches in identifying the candidate genes [22,23].

Cervical cancer genomes typically harbor multiple chromosome aberrations and epigenetic modifications, resulting in deregulated transcriptomes. These changes might play

---

Table 2. Mutational and epigenetic promoter hypermethylation alteration of genes in cervical cancer.

| Alteration | Invasive cancer | Precancerous lesions | Ref. |
|------------|----------------|---------------------|------|
| **Mutation** | | | | |
| Replicate studies | TP53, CDKN2A, PTEN | None | Supplementary online material | |
| Nonreplicate studies | HRAS, HLA B-15, HLA A-24, KRAS, BRAF, CD83, RNASL, PIK3CA, LKB1 | None | | |
| **Promoter hypermethylation** | | | | |
| Replicate studies | APC, CADM1, CALCA, CCNA1, CDKN2A, CDH1, CDH13, COX2, DAPK, FHI1, GSTP1, HIC1, MGMT, PCDH10, RARB, RASSF1A, THBS1, TIMP3 | CDKN2A, CCNA1, DAPK, MGMT | Supplementary online material | |
| Nonreplicate studies | AHR, BLU, C13ORF18, DPPX1, CAGE, CDKN2B, CHFR, ESR1, TP3, ESR1, FANCF, HLF1, IGSF4, MAL, MYD1, PGR, POU2F3, PTEN, SOC51, hTERT, HSPA2, MLH1, TWIST, SLIT1, SLIT2, SLIT3, ROBO1, ROBO3, SFRP1, SFRP2, SFRP4, SFRP5, SOCS2, SOX1, PAX1, LMX1A, NKX6–1, WT1, ONECUT1 | AHR, BLU, C13ORF18, CADM1, CCNA1, CDH1, CDH13, FHI1, GSTP1, LMX1A, MAL, hMLH1, NKX6–1, ONECUT1, PAX1, PCDH10, RARB, RASSF1A, ROBO1, ROBO3, SLIT1, SLIT2, SLIT3, SOCS2, SOX1, TIMP3, WT1 | | |

1One or more cases considered positive.
2Commonly seen in human papilloma virus-negative tumors.
3See www.futuremedicine.com/doi/suppl/10.2217/FON.10.114.
roles in driving malignant transformation. Understanding the relationship between multidimensional levels of genomic modifications might expand our knowledge of the molecular basis of CC. As stated previously, CC genomes are characterized by a number of recurrent genomic copy number losses and gains. Of those exhibiting gains, chromosomal regions 3q, 5p, 20q and 1q were the most common targets exhibiting gains, chromosomal regions 3q, 5p, 20q and 1q were the most common targets [9,101]. In this article, we focus the analysis on two of these genomic regions in CC, 5p and 20q, and the outcome of integrative genomic analysis using copy number increases and gene expression is presented.

Genomic & transcriptional analysis of chromosomes 5p & 20q
Genomic copy number alterations (CNAs) were identified utilizing Affymetrix (CA, USA) 250K NspI single nucleotide polymorphism (SNP) array platform and analyzed using the dChip software algorithms in 79 untreated primary CC samples [12,24]. Although this analysis uncovered a multitude of both known and unknown, as well as frequent and rare, altered CNAs, the 5p and 20q regions were the most significant recurrent focal copy number gains. Of these, the 5p CNA gains were found in 43% of tumors, and the 20q CNA gains or amplifications were found in 37% of tumors. The abundance of transcripts of protein-coding genes was measured by the Affymetrix U133A platform and analyzed using the dChip software algorithms among 42 CC cases [12,24]. Expression arrays were normalized using a median-intensity array from normal, as a baseline array using an invariant set normalization, as described previously [12,24]. Briefly, a list of differentially expressed genes with a twofold change was identified, with group means at 90% CIs. A list of overexpressed genes mapped to chromosomes 5 and 20 were identified further and used in subsequent supervised analyses using defined criteria to further obtain overexpressed gene signatures of specific chromosomal regions. The resulting gene expression datasets were utilized to correlate with 5p and 20q gains in order to identify expression patterns that were associated with CNAs.

Integrative genomic & transcriptional profiles identify target genes of 5p gains
We identified gains of the entire 5p chromosomal arm in CC and no minimal regions of amplification or gain could be delineated (Figure 1A). The duplications of entire chromosomal arms resulting from isochromosome formation in human tumors are not uncommon (e.g., i[12p] in male testicular germ cell tumor [28] and i[5p][10] in several types of adenocarcinomas and squamous cell carcinomas [101,102]). Since 5p gain was one of the most commonly affected regions in CC genomes, which was validated by fluorescence in situ hybridization assay on a large independent cohort of tumor specimens (Figure 1C), we hypothesize that the increased dosage of 5p may result in deregulation of genes that may confer oncogenic properties to its host cell [9]. To identify target genes of gain, we performed supervised analyses to compare and filter the overexpressed 5p gene set between 5p gains and diploid tumors to see what extent these two platforms will facilitate the identification of target genes. This analysis (using a significance level of p < 0.05 and at least twofold increased expression) identified 17 overexpressed genes associated with 5p gain (Figure 1B). In addition, these genes showed several-fold increased expression relative to GAPDH in tumors with 5p gains (>2 copies) compared with tumors showing only two copies (Figure 1D). Therefore, these genes represent copy number-driven target overexpressed genes, which probably provide growth advantages and/or invasion conferred by chromosome 5p gains.

This analysis identified concurrent 5p gains, with overexpression of potentially relevant genes to cellular processes associated with tumorigenesis, such as signal transduction (OSMR), nucleic acid binding, DNA repair, mitotic cycle (BASP1, TARS, PAIP1, BRD9, RAD1, SKP2 and POLS), oxidative phosphorylation (NNT, SDHA and NDUF56), HPV 16 E1 binding protein (TRIP13), ribosomal synthesis (BXDC2) and miRNA processing (RNASEN). The top overexpressed gene by this analysis was RNASEN (Drosha), which executes the initial step in miRNA processing by cleaving pri-miRNA to release pre-miRNA, and plays a major role in tumor progression and prognosis [26]. Muralidhar et al., using a similar integrative approach, have also identified that Drosha copy number increases associated with the overexpression of this gene in CC, and Drosha overexpression was further shown to influence expression of miRNAs implicated in other cancer types [27]. Another gene of importance in cancer is OSMR, which has been shown to be gained and overexpressed in CC and is associated with adverse clinical outcome [28,29]. Oncostatin M is a cytokine related to the IL-6 family of cytokines, and its biological activity is mediated through the receptor complex. Upon ligand binding, oncostatin M receptor activates signaling pathways implicated in cancer, such as...
STAT, PI3/AKT and angiogenic factor VEGF, and mediates inhibition of tumor growth [30]. The other genes identified in this analysis as a consequence of 5p gains possess functions related to nucleic acid binding, DNA repair and mitotic cell cycle (BASP1, TARS, PAIP1, BRD9, RAD1, SKP2 and POLS) and nuclear genes (NNT, SDHA and NDUFS6) encoding mitochondrial proteins that play a role in oxidative phosphorylation. Dowen et al. showed that upregulation of SKP2 gene transcription relates to 5p gains in CC cell lines [31]. SKP2 is an F-box family protein that plays a critical role in G1/S cell cycle progression and degrades CDKN1B (p27kip). However, a similar integrated gene dosage and expression analysis by Lando and coworkers found a different set of target genes on 5p than we identified in our study [32]. Although the exact role of these overexpressed genes on 5p in CC remains unknown, their identification provides a basis for dissecting the signaling cascades involving their role individually or synergistically as oncogenes in regulating the transformation in CC.

![Figure 1. Integrated analyses of chromosome 5p genomic alterations in cervical cancer.](image)

**A** Copy number alterations in log2 ratio of chromosome 5 identified by 250K NspI single nucleotide polymorphism (SNP) array in normal and tumor tissue. Each vertical column represents a sample with genomic regions representing from pter (top) to qter (bottom). The blue–red scale bar (-1.0 to +1.0) at the bottom represents the copy number changes relative to the mean across the samples. **B** Supervised analysis of overexpressed genes identified as a consequence of gain of chromosome 5p. G-banded ideogram of chromosome 5 is shown on the left. Significantly, differentially overexpressed genes identified between tumors showed more than two copies of 5p, and tumors with two copies of 5p are shown. In the matrix, each row represents the gene expression relative to group mean and each column represents a sample. Overall, as expected, cell lines exhibited higher levels of expression differences than primary tumors (data not shown). The scale bar (-2.0 to +2.0) on the bottom represents the level of expression. **C** Fluorescence in situ hybridization identification of 5p gains in invasive cancer. Green signals represent the 5p15.2 probe and red signals represent the probe mapping to the 5q31 region used as control. **D** Relative expression of differentially expressed genes as a consequence of 5p gain in relation to glyceraldehyde 3-phosphate dehydrogenase in normal and tumors with and without 5p gain is shown in box plot distribution. Middle line across the box represents median value, the upper hinge represents the 75th percentile value and the lower hinge the 25th percentile. The minimum and maximum value data points are shown below and above the box, respectively. GADPH: Glyceraldehyde-3-phosphate dehydrogenase.
Chromosome 20q gains were also shown to be associated with HPV E-7-mediated immortalization of human epithelial cells [36]. These data suggest that 20q amplification is an early change in CC development, and the concurrent overexpression of specific gene(s) on this genomic region might be critical to transformation. Our copy number SNP array analysis of chromosome 20 identified two recurrent and nonoverlapping focal amplicons on 20q at 20q11.2 and 20q13.13 (Figure 2) [24]. The minimum shared region of amplicons at 20q11.2 spans a 4.1-Mb genomic region, and the amplicons at 20q13.13 span a 3.1-Mb physical distance (Figure 2). Since chromosome 20q is one of the commonly gained regions in CC genomes, we hypothesize that the amplicons located within 20q may induce transcriptional activation of specific genes relevant to cellular transformation. Integrative genomic CNAs and expression data analysis identified eight overexpressed genes in amplicon 20q11.2 and six in amplicon 20q13.13 (Figure 2). The eight overexpressed genes in amplicon 20q11.2 are GSS, POFUT1, AHCY, TPX2, ASXL1, E2F1, RALY and KIF3B. These genes are functionally associated with amino acid metabolism/oxidative stress (GSS and AHCY), a Notch signaling pathway (POFUT1), cell cycle regulation (TPX2, E2F1 and KIF3B), a putative polycomb-group protein (ASXL1) and an RNA-binding protein (RALY). The overexpressed genes in the interval of 20q13.13 amplicons include nucleotide binding (ATP9A and DDX27), activity-dependent neuroprotector (ADNP) with a potential role in tumor proliferation,

**Figure 2.** Chromosome 20q amplification target genes and their pathways identified by integrated analysis of copy number and gene expression. A G-banded ideogram of chromosome 20 is shown at the top. Representative cases of SNP array copy numbers by 250K HspI array in log2 ratio are shown. Each horizontal column in the SNP array represents a sample with genomic region, representing pter (top) to qter (bottom). The blue–red scale bar (-1.0 to +1.0) at the top represents the copy number changes relative to mean across the samples. Downward arrows show two focal amplicons on 20q, identified by SNP array. Significantly overexpressed genes identified and the pathways the genes connected as a consequence of 20q amplifications are shown in the figure. SNP: Single nucleotide polymorphism.
a gene encoding for UDP-Gal:β-GlcNAc β-1,4-galactosyltransferase (B4GALT5) with transferase activity, a zinc finger protein 313 (ZNF313) and a nuclear function protein (CSE1L). The genes that we found to be upregulated as a consequence of chromosome 20q amplifications are known to play specific roles in tumorigenic processes. For example, E2F1, KIF3B, TPX2 and CSE1L genes play pivotal roles in cell cycle regulation and chromosome segregation (Figure 2). Therefore, the genes identified by this approach provide a basis for testing their significance in relation to HPV infection, a functional role in tumor initiation and progression of CC. Recently, Lando and coworkers, using integrative analysis of gene dosage and expression, also found three of the genes (POFUT1, KIF3B and AHCY) that we identified to be overexpressed as targets of 20q gain [32]. However, Wilting and coworkers, in a similar approach utilizing a smaller sample size and whole-genome analysis using differential gene locus mapping and array comparative genomic hybridization expression integration tool, did not identify any of the genes we identified in our study [37]. Therefore, these studies highlight the importance of the application of appropriate algorithms of integrative genomic approaches to identify gene targets that are biologically relevant to cervical carcinogenesis.

Conclusion
In this article, we have described an integrative genomic strategy utilizing information on recurrent CNAs at 5p, 20q11.2 and 20q13.13, with gene expression to identify genes relevant to genomic copy number gains and amplifications. Utilizing this approach, we demonstrated the robustness of this strategy in identifying genes and genetic pathways relevant to a specific region of genomic copy number increases in tumorigenesis. We conclusively show that a simple approach of systematic integrative genomic analysis can lead to better molecular discoveries, which could then be used in identifying relevant therapeutic targets for CC.

Future perspective
To gain insight into molecular-based therapeutic targets for patients with CC, it is essential to construct an integrated view of multidimensional genomic data from complementary technologies for CNA (gains, amplifications and deletions) with transcription profiles, mutations, miRNA, epigenetic markers and clinical end points. It would be reasonable to speculate such an approach – complemented by appropriate bioinformatics tools and functional data – is likely to advance our molecular knowledge to identify core pathways, leading to individualized molecular-based therapy. Advances in molecular knowledge will also change the detection and prediction of precancerous lesion, making the existing tests obsolete. Among the first hints at this approach is the integrative genomic analysis that we discussed in this article. A significant reduction in the incidence of CC has been already achieved by Pap smear screening. The availability of a prophylactic HPV vaccine is expected to further reduce this incidence. Almost certainly, the advances in molecular and bioinformatic technologies will further enhance our molecular understanding and continue to raise the hope for high cure rates of CC.

Executive summary
- Amplification of over 20 different chromosomal regions has been reported in cervical cancer (CC).
- CC genomes harbor multiple copy number gains and losses of specific chromosomal regions; some of these were shown to arise at early precancerous stages, suggesting a role for copy number alterations in its tumorigenesis.
- Mutational mechanisms are relatively uncommon in CC.
- Promoter hypermethylation and the associated downregulated gene expressions are frequent in CC.
- The chromosomal regions of 5p and 20q exhibit the most significant recurrent focal copy number alterations in CC, suggesting their role in tumor formation and progression.
- Integrative genomic analysis of 5p gains and 20q11.2 and 20q13.13 amplifications identified overexpressed genes as a consequence of genomic copy number increases. The genes identified are involved in cellular processes associated with specific pathways in tumorigenesis.

Future Oncol. (2010) 6(10)
Integrative genomic approaches in cervical cancer: implications for molecular pathogenesis

Review

Bibliography

Papers of special note have been highlighted as:
- of interest
  - of considerable interest

1. Jemal A, Siegel R, Ward E et al.: Cancer statistics, 2009. CA Cancer J. Clin. 59(4), 225–249 (2009).
2. Murthy NS, Sehgal A, Satyanarayana L et al.: Risk factors related to biological behaviour of precancerous lesions of the uterine cervix. Br. J. Cancer 61(5), 732–736 (1990).
3. Schneider A, Koutsy LA: Natural history and epidemiological features of genital HPV infection. IARC Sci. Publ. 119, 25–52 (1992).
4. Dunne EF, Markowitz LE: Genital human papillomavirus infection. Clin. Infect. Dis. 43(5), 624–629 (2006).
5. Richart R, Ludwig AS Jr: Alterations in chromosomes and DNA content in gynecologic neoplasms. Am. J. Obstet. Gynecol. 104(4), 463–471 (1969).
6. Wakonig-Vaartaja R, Hughes DT: Chromosomal abnormalities in dysplasia, carcinoma-in-situ, and carcinoma of cervix uteri. Lancet 2(7416), 756–759 (1965).
7. Santarius T, Shipley J, Brewer D et al.: A census of amplified and overexpressed human cancer genes. Nat. Rev. Cancer 10(1), 59–64 (2010).
8. Narayan G, Arias-Pulido H, Koul S et al.: Genetic analysis identifies putative tumor suppressor sites at 2q35–q36.1 and 2q36.3–q37.1 involved in cervical cancer progression. Oncogene 22(22), 3489–3499 (2003).
9. Rao PH, Arias-Pulido H, Lu XY et al.: Chromosomal amplifications, 3q gain and deletions of 2q43–q37 are the frequent genetic changes in cervical carcinoma. BMC Cancer 4(1), 5 (2004).
10. Heselmeyer K, Schrock E, du Manoir S et al.: Gain of chromosome 3q defines the transition from severe dysplasia to invasive carcinoma of the uterine cervix. Proc. Natl Acad. Sci. USA 93(1), 479–484 (1996).
11. Heselmeyer K, Macville M, Schrock E et al.: Advanced-stage cervical carcinomas are defined by a recurrent pattern of chromosomal aberrations revealing high genetic instability and a consistent gain of chromosome arm 3q. Genes Chromosomes Cancer 19(4), 233–240 (1997).
12. Scotto L, Narayan G, Nandula SV et al.: Integrative genomics analysis of chromosome 5p gain in cervical cancer reveals target over-expressed genes, including Drosha. Mol. Cancer 7, 58 (2008).
13. Dong SM, Kim HS, Rha SH, Sidransky D: Promoter hypermethylation of multiple genes in carcinoma of the uterine cervix. Clin. Cancer Res. 7(7), 1982–1986 (2001).
14. Narayan G, Scotto L, Neelakantan V et al.: Protocadherin PCDH10, involved in tumor progression, is a frequent and early target of promoter hypermethylation in cervical cancer. Genes Chromosomes Cancer 48(11), 983–992 (2009).
15. Narayan G, Arias-Pulido H, Koul S et al.: Frequent promoter methylation of CDH1, DAPK, RARB, and HIC1 genes in carcinoma of cervix uteri: its relationship to clinical outcome. Mol. Cancer 2, 24 (2003).
16. Virmani AK, Muller C, Rathi A et al.: Aberrant methylation during cervical carcinogenesis. Clin. Cancer Res. 7(3), 584–589 (2001).
17. Hidalgo A, Baudis M, Petersen I et al.: Microarray comparative genomic hybridization detection of chromosomal imbalances in uterine cervix carcinoma. BMC Cancer 5, 77 (2005).
18. Wilting SM, Smeets SJ, Snijders P et al.: Cancer genome identification of candidate amplified and over-expressed genes. Genes Chromosomes Cancer 46(4), 373–384 (2007).
19. Kloth JN, Oosting J, van Wezel T et al.: Combined array-comparative genomic hybridization and single-nucleotide polymorphism-loss of heterozygosity analysis reveals complex genetic alterations in cervical cancer. BMC Genomics 8, 53 (2007).
20. Lockwood WW, Coe BP, Williams AC, MacAulay C, Lam WL: Whole genome tiling panel analysis of segmental copy number alterations in cervical cancer cell lines. Int. J. Cancer 120(2), 436–443 (2007).
21. Fitzpatrick MA, Funk MC, Gius D et al.: Identification of chromosomal alterations important in the development of cervical intraepithelial neoplasia and invasive cervical cancer using alignment of DNA microarray data. Gynecol. Oncol. 103(2), 458–462 (2006).
22. Boehm JS, Zhao JJ, Yao J et al.: Integrative genomic approaches identify IKBKE as a breast cancer oncogene. Cell 129(6), 1065–1079 (2007).
23. The TCGA Research Network: Comprehensive genomic characterization defines human glioblastoma genes and core pathways. Nature 455(7216), 1061–1068 (2008).
24. Scotto L, Narayan G, Nandula SV et al.: Identification of copy number gain and over-expressed genes on chromosome arm 20q by an integrative genomic approach in cervical cancer: potential role in progression. Genes Chromosomes Cancer 47(9), 755–765 (2008).
25. Chaganti RS, Houldsworth J: Genetics and biology of adult human male germ cell tumors. Cancer Res. 60(6), 1475–1482 (2000).
26. Sugito N, Ishiguro H, Kuwabara Y et al.: RNASEN regulates cell proliferation and affects survival in esophageal cancer patients. Clin. Cancer Res. 12(24), 7322–7328 (2006).
27. Muralidhar B, Goldstein LD, Ng G et al.: Global microRNA profiles in cervical squamous cell carcinoma depend on Drosha expression levels. J. Pathol. 212(4), 368–377 (2007).
28. Narayan G, Bourdon V, Chaganti S et al.: Gene dosage alterations revealed by cDNA microarray analysis in cervical cancer: identification of candidate amplified and over-expressed genes. Genes Chromosomes Cancer 46(4), 373–384 (2007).
29. Ng G, Winder D, Muralidhar B et al.: Gain and overexpression of the oncostatin M receptor occur frequently in cervical squamous cell carcinoma and are associated with adverse clinical outcome. J. Pathol. 212(3), 325–334 (2007).
30. Liu J, Hadjokas N, Mosley B et al.: Oncostatin M-specific receptor expression and function in regulating cell proliferation of normal and malignant mammary epithelial cells. Cytokine 10(4), 295–302 (1998).
31. Downey SE, Neutez DM, Pett MR et al.: Amplification of chromosome 5p correlates with increased expression of Skp2 in HPV-immortalized keratinocytes. Oncogene 22(16), 2531–2540 (2003).
32. Lando M, Holden M, Bergersen LC et al.: Gene dosage, expression, and ontology analysis identifies driver genes in the carcinogenesis and chemoradioresistance of cervical cancer. PLoS Genet. 5(11), E1000719 (2009).

33. Wilting SM, Snijders PJ, Meijer GA et al.: Increased gene copy numbers at chromosome 20q are frequent in both squamous cell carcinomas and adenocarcinomas of the cervix. J. Pathol. 209(2), 220–230 (2006).

34. Wilting SM, Steenbergen RD, Tijssen M et al.: Chromosomal signatures of a subset of high-grade premalignant cervical lesions closely resemble invasive carcinomas. Cancer Res. 69(2), 647–655 (2009).

35. Alazawi W, Pett M, Strauss S et al.: Genomic imbalances in 70 snap-frozen cervical squamous intraepithelial lesions: associations with lesion grade, state of the HPV16 E2 gene and clinical outcome. Br. J. Cancer 91(12), 2063–2070 (2004).

36. Klingelhoitz AJ, Qian Q, Phillips SL et al.: Amplification of the chromosome 20q region is associated with expression of HPV-16 E7 in human airway and anogenital epithelial cells. Virology 340(2), 237–244 (2005).

37. Wilting SM, de Wilde J, Meijer CJ et al.: Integrated genomic and transcriptional profiling identifies chromosomal loci with altered gene expression in cervical cancer. Genes Chromosomes Cancer 47(10), 890–905 (2008).

Websites
101. Progenetix www.progenetix.com/progenetix/G_Cervixca
102. National Cancer Institute. Recurrent chromosome aberrations in cancer http://cgap.nci.nih.gov/Chromosomes/RecurrentAberrations